Peptide RegisterUK

Independent UK reference

What these drugs actually are.

The information already exists, in regulatory documents, trial papers and the BNF. It is just scattered and hard to read. Every entry here pulls it into one record, in the same order, and links back to the primary source.

  • Nothing sold
  • No doses or protocols
  • No affiliate links
  • No advertising
Record 01

Semaglutide

GLP-1 receptor agonist
MHRA licensed Prescription only Evidence: human RCT

Peptide sequence, one-letter notation

H·Aib·EGTFTSDVSSYLEGQAAK·EFIAWLVRGRG

Compound class

A 31-amino-acid analogue of human GLP-1, a hormone released by the gut after eating. Modified so it lasts about a week in the body rather than minutes.

Licensed for

Type 2 diabetes and weight management, under separate authorisations with separate brands and separate criteria. Which is why Ozempic and Wegovy are not interchangeable.

How it works

Binds the GLP-1 receptor. More insulin when glucose is high, slower stomach emptying, and reduced appetite signalling in the brain.

Sources
Record checked 25 July 2026 Read the full record

The register

Every compound, the same six sections

UK status comes first, because it is the thing most often misrepresented elsewhere. Licensed medicine, unlicensed, and research use only are three completely different legal and safety positions.

CompoundClassUK statusEvidence
SemaglutideOzempic, Wegovy, Rybelsus GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
TirzepatideMounjaro Dual GIP and GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
LiraglutideSaxenda, Victoza GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
DulaglutideTrulicity GLP-1 receptor agonist MHRA licensed Human RCT, phase 3
OrforglipronFoundayo in the United States. No UK brand name yet Non-peptide GLP-1 receptor agonist Not licensed in the UK Human RCT, phase 3
RetatrutideNo brand name. Development code LY3437943 Triple receptor agonist Not licensed anywhere Phase 3 ongoing
CagriSemaNo brand name. A combination of cagrilintide and semaglutide Amylin analogue plus GLP-1 receptor agonist Not licensed anywhere Phase 3 reported, no approval
TesamorelinEgrifta GHRH analogue Not licensed in the UK Human RCT for its licensed indication
SomatropinMultiple brands, including Genotropin, Norditropin, Humatrope Recombinant human growth hormone Licensed, and a Class C controlled drug Human RCT for licensed uses
BPC-157Also written BPC 157, Bepecin, PL 14736 Synthetic pentadecapeptide Unlicensed medicine Animal studies, almost no human data
TB-500Related to thymosin beta-4, often conflated with it Synthetic peptide fragment Unlicensed medicine Animal studies, no human trials
CJC-1295Also sold as Mod GRF 1-29 or CJC-1295 no-DAC, which is a related but shorter-acting compound GHRH analogue Unlicensed medicine No human trials supporting marketed claims
IpamorelinNo brand name. Sold as a research chemical, usually blended with CJC-1295 Growth hormone secretagogue Unlicensed medicine Abandoned in development, no supporting human trials
AOD-9604Also written hGH 176-191 or hGH fragment 176-191 Growth hormone fragment Unlicensed medicine Human trials did not support the claims
MK-677Ibutamoren, ibutamoren mesylate, sometimes sold as Nutrobal Growth hormone secretagogue, non-peptide Unlicensed medicine Human trials exist, no approval
Melanotan IIMT-II, sold as tanning injections and nasal sprays Synthetic melanocortin receptor agonist Unlicensed medicine Limited early human studies

See the full register

Start here

Three things worth reading first

Foundations

What a peptide actually is

Insulin is one. So is Mounjaro. So is the powder sold in an unlabelled vial. The word covers all three, which is why it gets used so loosely.

Regulation

Licensed, unlicensed, research use only

Three labels that decide whether anything has been checked. The phrase not for human consumption on a vial is a legal position, not a quality statement.

Method

How to read a claim

Who ran the study, how many people, what it measured, and who paid. Most figures circulating online answer a narrower question than the claim suggests.

Method

How a record gets built

  1. Start at the regulatorLicensing status and approved indications from the MHRA and the SPC, never from a secondary write-up.
  2. Add the clinical referenceMechanism, cautions and interactions from the BNF. Funding criteria from NICE.
  3. Trace every numberEach reported effect tied to the named trial it came from, with the funder stated.
  4. State what is missingWhere there is no human data, the record says so plainly instead of filling the gap.

Sources used

Where this comes from

  • MHRALicensing, safety alerts, Yellow Card
  • electronic medicines compendiumSummaries of Product Characteristics
  • BNFClinical monographs
  • NICETechnology appraisals
  • NHS EnglandAccess pathways and patient guidance
  • PubMed and CochraneTrials and systematic reviews
  • WADAProhibited list for athletes

See the full source list